Merck Revenues Fall in Quarter 3

Merck & Co have seen revenues drop by 4 per cent in their third quarter, as their diabetes blockbuster, Januvia, continued to show signs of weakness in the US. Sales were reported to be $11 billion, with Merck’s DPP-4 inhibitor Januvia (sitagliptin) down 5% to $927 million.  Line extension Janumet (sitagliptin and metformin) fared slightly

Continue Reading

Eli Lilly Announces Strong Q3 2013

Eli Lilly have revealed a positive set of financials for their third quarter of 2013, which was aided by cost-cutting and continued strong sales of Cymbalta. Net income dropped by 9% to $1.20 billion, although it is worth noting that Eli Lilly’s results from Q3 of 2012 included an early payment of $787 million from

Continue Reading

Roche Announces Positive Q3 Results

Roche have revealed positive financial results for the third quarter, strengthened by the sustained growth of their cancer drugs. Earlier today Roche announced that sales reached 11.57 billion Swiss francs, an increase of 8%, while their pharmaceutical revenue grew by 9% to 9.03 billion Swiss francs. Roche’s best-selling drug was MabThera/Rituxan (rituximab), which has been

Continue Reading

Janssen Pharmaceuticals Acquire GSK Antiviral

Johnson & Johnson’s Janssen Pharmaceuticals has acquired an investigational antiviral from GlaxoSmithKline (GSK) with the aim to develop an oral regimen for the treatment of hepatitis C (HCV). The pharmaceutical company has paid to obtain access to the NS5a replication complex inhibitor GSK2336805, which GlaxoSmithKline and their partner, Vertex, had taken up to clinical Phase

Continue Reading

AbbVie and Galapagos Sign $405 Million Agreement

After recently signing an anti-inflammatory deal with Ablynx, AbbVie has now announced a new agreement with Galapagos in cystic fibrosis. Specifically, the organisations have confirmed that they will contribute technologies and resources to develop oral drugs that address the main mutations in cystic fibrosis patients, including F508del and G551D, with the intention of starting Phase

Continue Reading

Physicians 2 Pharma Workshop

Only Medics will be hosting a day of workshops for medics looking to transition to the pharmaceutical industry. The workshop will take place on Thursday 26th September in Reading, UK.  Attendance to the workshop is by invitation only. In addition to medics, the workshop will be attended by industry physicians and HR professionals, some of whom are actively

Continue Reading

AstraZeneca Partners with Merck & Co

AstraZeneca have announced that they have licensed a drug which is currently in mid-stage clinical studies for ovarian cancer from Merck & Co. The agreement revolves around MK-1775, an oral small molecule inhibitor of WEE1 kinase, a cell cycle checkpoint protein regulator. Preclinical results have indicated that disruption of WEE1 may improve the cell killing

Continue Reading